Outlook for Disgorgement Remedies in the Trump Administration
Price discrimination in the pharmaceutical sector: new decision, but plaintiffs face same challenges
Outlook for 2015: Antitrust Litigation in the Pharma Industry – More Than Just Actavis Progeny
Federal Circuit Revives Certain Sham Petitioning Antitrust Counterclaims in Tyco-Mutual ANDA Litigation
Defining “Payments”: The First Post-Actavis Battleground in Pharmaceutical Reverse Payments
DOJ and FTC to Shine Spotlight on Analysis of Conditional Pricing Practices Under the Antitrust Laws
CT AG Leads Charge to Increase Transparency of Hospital-Physician Acquisitions and Facility Fees
Actelion Settles REMS Dispute with Generic Drug Manufacturers
NY Attorney General Forges New Ground in Scrutiny of Pharmaceutical Agreements With First-Filer Exclusivity No-Challenge Settlement
Blogs
Firm/Org